EyeGene KRX:185490KOSDAQ

아이진 · Korean news coverage and regulatory filings, organized.

Articles, 24h0
Articles, 7 days2
DART filings, 7 days3
Articles tracked17since Sep 11

In Q3 2026, EyeGene reported revenue of ₩1.2bn, up 6.1% year on year, and an operating loss of ₩2.5bn. EyeGene (아이진) appeared in 2 Korean news articles and 3 DART filings over the past seven days. Coverage peaked on Nov 10 with 1 article. It was most often mentioned alongside EG and Daesang.

Filing signals Insider buying Major holder adding Clinical trial filing 4 quarters of losses Screener

EyeGene at a glance from DART filings

Results trend
Operating loss in each of the last 4 quarters; Q3 2026 operating loss of ₩2.5bn a loss again after the previous quarter.
Ownership changes
3 5%-holder and insider ownership reports in the past 120 days (3 increases, 0 decreases).

Figures the company filed on DART, grouped by ATS View. Not a buy or sell call; see the cards below and the DART originals.

EyeGene today: up or down?

No sign-up, one tap a day. These numbers show what visitors think and are not investment advice.

Upcoming dates as filed

  • Mar 31 Annual report filing deadlinein 134 days · period ending Dec 2026

Dates EyeGene stated in its DART filings. A conversion period opening does not mean new shares appear that day; bondholders must request conversion.

EyeGene quarterly results consolidated, KRW

QuarterRevenueYoYOperating profitNet income
Q3 2026₩1.2bn+6.1%−₩2.5bn
margin −215.2%
−₩2.3bn
Q2 2026₩1.3bn+52.7%−₩3.9bn
margin −294.8%
−₩3.8bn
Q1 2026₩1.3bn+55.6%−₩3.5bn
margin −277.7%
−₩3.6bn
Q4 2025 derived₩774m-41.0%−₩3.3bn−₩12.1bn
Q3 2025₩1.1bn+14.4%−₩1.6bn
margin −150.1%
−₩1.6bn
Q2 2025₩877m+56.3%−₩2.5bn
margin −279.6%
−₩2.5bn
Q1 2025₩818m+56.3%−₩2.5bn−₩3.0bn
Q4 2024 derived₩1.3bn+8.1%−₩2.4bn
margin −180.8%
−₩2.7bn

EyeGene ranks #2026 of 2,345 Korean listed companies by Q3 2026 operating profit. Q3 2026 Korean earnings rankings →

Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.

EyeGene top stories 2 weeks, by number of outlets

  1. 1
  2. 2

Latest EyeGene news Korean headlines